Corrected: BUZZ-India's Dr Reddy's falls on semaglutide supply delay due to API issue

Dr. Reddy's Laboratories

09/07/2026 05:19

Corrects headline and text to say Dr Reddy's will delay semaglutide supply, not production
** Dr Reddy's Laboratories REDY.NS fell as much as 2.7% to 1,312.10 rupees, before paring losses to trade 0.4% lower
** Pharmaceuticals co says commercial supply of semaglutide will be delayed due to an issue associated with the active pharmaceutical ingredient
** "There is no impact on patient safety or on the product's existing global regulatory filings," REDY says
** YTD, REDY up ~4%

 (Reporting by Vijay Malkar)
 ((VijayDattaram.Malkar@thomsonreuters.com;))